Clinical Trials
29 trialsMultitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillance
National Institutes of Health Clinical Center (CC)
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
National Institutes of Health Clinical Center (CC)
SPiReL
Sunnybrook Health Sciences Centre
ROWAN
Boston Scientific Corporation
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
ACCESS
Center for International Blood and Marrow Transplant Research
OPTIC
Takeda
OPTIMIZE
Center for International Blood and Marrow Transplant Research
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
Pfizer
VIRO-25
Genelux Corporation
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
Juno Therapeutics, a Subsidiary of Celgene
Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer
The First Affiliated Hospital with Nanjing Medical University
ALTER-E005
Jiangxi Provincial Cancer Hospital
A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment
Hellenic Society of Hematology
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
Hellenic Society of Hematology
Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL
The First Affiliated Hospital with Nanjing Medical University
AVANIRA3
Jiangsu Cancer Institute & Hospital
ANLOLA
Jiangsu Cancer Institute & Hospital
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Seagen Inc.
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma
Seagen Inc.
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
Royal Marsden NHS Foundation Trust
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Shanghai Pulmonary Hospital, Shanghai, China
Intra-arterial Y-90 TheraSpheres for Hepatic Metastases From Solid Tumors
Yale University
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Novartis
NET
Assistance Publique - Hôpitaux de Paris
SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma
National Cancer Institute (NCI)
Fibrolam
Assistance Publique - Hôpitaux de Paris
Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma
Shandong Cancer Hospital and Institute